Aerosolized tobramycin: Can differences in nebulizers efficency influence particles size and deposition in the lower airways?;Aerosol di tobramicina: Può il sistema di erogazione influenzare le caratteristiche granulometriche e la deposizione nelle vie aeree inferiori?

Recenti Progressi in Medicina

Volumn 89, Issue 5, 1998, Pages 245-249

  Terzano, Claudio ^a   Mannino, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Aerosol; Jet nebulizers; Mass median aerodynamic diameter; Particle size; Tobramycin

Indexed keywords

TOBRAMYCIN; ANTIINFECTIVE AGENT;

AEROSOL; ARTICLE; BRONCHIECTASIS; BRONCHIOLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISPERSION; LUNG ALVEOLUS; LUNG DEPOSIT; MEDICAL NEBULIZER; PARTICLE SIZE; PSEUDOMONAS AERUGINOSA; SPECTROMETER; TRACHEOBRONCHIAL TREE; CHEMISTRY; DRUG DELIVERY SYSTEM; INSTRUMENTATION; LUNG;

AEROSOLS; ANTI-BACTERIAL AGENTS; DRUG DELIVERY SYSTEMS; LUNG; PARTICLE SIZE; TOBRAMYCIN;

EID: 0032059136     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Smith AL, Ramsey B. Aerosol administration of antibiotics. Respiration 1995; 62 (suppl 1 ): 19-24.
2. Pascal S,Diot P, Lemarié E. Antibiothérapie en aérosol. Rev Mal Resp 1992; 9: 145-153.
3. Simonds AK, Newman SP, Johnson MA, Talaee N, Lee CA, Clarke SW. Alveolar targeting of aerosol Pentamidine. Am Rev Resp Dis 1990; 141: 827-9.
4. Mukhopadhyay S, Staddon GE, Eastman C, Palmer M, Rhys Davies E, Carswell F. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respiratory Medicine 1994; 88: 203-11.
5. Gooch MD. Stability of albuterol and tobramycin when mixed for aerosol administration. Respiratory Care 1991; 36: 1387-90.
6. Cooney GF, Lum BL, Tomaselli M, Fiel SB. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis J Clin Pharmacol 1994; 34: 255-9.
7. Weber A, Smith A, Williams Warren J, Ramsey B, Covert DS. Nebulizer delivery of tobramycin to the lower respiratory tract. Pediatr Pulmonol 1994; 17: 331-9.
8. Littlewood JM, Smye SW, Cunliffe H. Aerosol antibiotic treatment in cystic fibrosis. Arch Dis Child 1993; 68: 788-92.
9. Wall MA, Terry AB, Eisenberg J, Mc Namara M, Cohen R. Inhaled antibiotics in cystic fibrosis. Lancet 1983; i: 1325.
10. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. New Engl J Med 1993; 24: 1740-6.
11. Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981; ii: 1137-9.
12. Kohler D, Fleischer. Established facts in inhalation therapy. München: Arcis Verlag 1991; 40-1.
13. Valcke Y, Pawels R, Van Der Straeten M. Pharmacokinetics of antibiotics in the lung. Eur Respir J 1990: 3; 715-22.
14. Makhoul IR, Merzbach D, Lichtig C, Berant M. Antibiotic treatment of experimental Pseudomonas aeruginosa pneumonia in guinea pig. Comparision of aerosol and systemic administration. JID 1993; 168: 1296-9.
15. Breese Hall C, Mc Bride JT. Pulmonary infections. In: Aerosols in Medicine. Principles, diagnosis and therapy. Amsterdam: Elsevier 1993: 291-300.
16. Cheng YS, Barr EB, Marshall IA, Mitchel JP. Calibration and performance of an API aerosizer. J Aerosol Sci 1993; 24: 501-14.
17. Niven Ralph W. Aerodynamic particle size testing using a time-of-flight aerosol beam spectrometer. Pharm Technol, 1993; 1: 72-8.
18. Atkins PJ. Aerodynamic particle size testing-impringer methods. Pharm Technol 1992; 8: 26-32.
19. Schwartz MX, Andres RP. Theoretical basis of the time-of flight aerosol spectrometer. A method for monitoring the size distribution of submicron aerosol particles. J Aerosol Sci 1976; 7: 281-96.
20. Terzano C, Mannino F. Probability of particle and salbutamol deposition in the respiratory tract: comparison between MDI and autohaler ™. Monaldi Arch Chest Dis 1996; 51: 236-42.
21. Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005-15 mm. J Aerosol Sci 1986; 17: 811-25.
22. Stahlhofen W, Gebhart G, Heyder J, Scheuch G. New regional deposition data on the human respiratory tract. J Aerosol Sci 1983; 14: 186-8.
23. Stahlhofen W, Gebhart G, Heyder J, Scheuch G. Deposition pattern of droples from medical nebulizer in the human respiratory tract. Bull Eur Physiopatol Respir 1983; 19: 459-63.
24. Stahlhofen W. Human data on deosition. In: Proceedings of a joint meeting CEC/NRPB in Oxford (Smith H and Gerber G eds). Luxemburg: Office of the European Communities 1984; 39-62.
25. Vidgrén M. Factors influencing lung deposition of inhaled aerosol. Eur Respir Rev 1994; 4: 68-70.
26. Faurisson F, Dessanges JF, Grimfeld A, et al. Nebulizer performance: AFLM study. Respiration 1995; 62: 13-18.